NCT05509634View on ClinicalTrials.gov

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

PHASE3CompletedINTERVENTIONAL
Enrollment

754

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

June 19, 2023

Study Completion Date

August 30, 2023

Conditions
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Interventions
DRUG

HR20013 for injection；dexamethasone

"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"

DRUG

fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone

"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center Yuexiu Campus, Guangzhou

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY